Phase I trial of fludarabine and paclitaxel in non-Hodgkin's lymphoma

Muhammad R. Abbasi, Joseph A. Sparano, Catherine Sarta, Peter H. Wiernik

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Fludarabine is an active agent in low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Paclitaxel is also active in patients with refractory lymphoma, and preclinical data suggest an additive effect with fludarabine in vitro. We performed a phase I trial of fludarabine (25 mg/m2 d 1-3) plus a 3-h infusion of paclitaxel (125,150, or 175 mg/m2) on d 3 every 28 d in 13 patients with non-Hodgkin's lymphoma. The paclitaxel dose was escalated in cohorts of 3-4 patients using standard phase I design schema. Dose-limiting toxicity was defined as febrile neutropenia, platelet nadir less than 50,000/μL, or grade 3-4 nonhematologic toxicity. Thirteen patients were accrued to the study, 8 of these 13 patients (62%) had received prior chemotherapy. At the 125-, 150-, and 175-mg/m2 dose levels of paclitaxel, dose-limiting toxicity occurred in 1/4, 0/4, and 0/4 patients, respectively. The single patient with dose-limiting toxicity had febrile neutropenia. Partial response occurred in two of eight patients with low-grade lymphoma and none of five patients with other types of lymphoma. A paclitaxel dose of 175 mg/m2 given as a 3-h infusion on d 3 in conjunction with fludarabine (25 mg/m2 d 1-3 every 4 wk) is a well-tolerated regimen for non-Hodgkin's lymphoma. Further study will be required in order to determine whether the fludarabine-paclitaxel is more active than fludarabine alone in patients with low-grade lymphoma and chronic lymphocytic leukemia.

Original languageEnglish (US)
Pages (from-to)53-58
Number of pages6
JournalMedical Oncology
Volume20
Issue number1
DOIs
StatePublished - 2003

Fingerprint

Paclitaxel
Non-Hodgkin's Lymphoma
Febrile Neutropenia
B-Cell Chronic Lymphocytic Leukemia
Lymphoma
fludarabine
Blood Platelets
Drug Therapy

Keywords

  • Fludarabine
  • Non-Hodgkin's lymphoma
  • Paclitaxel
  • Phase I trial

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase I trial of fludarabine and paclitaxel in non-Hodgkin's lymphoma. / Abbasi, Muhammad R.; Sparano, Joseph A.; Sarta, Catherine; Wiernik, Peter H.

In: Medical Oncology, Vol. 20, No. 1, 2003, p. 53-58.

Research output: Contribution to journalArticle

Abbasi, Muhammad R. ; Sparano, Joseph A. ; Sarta, Catherine ; Wiernik, Peter H. / Phase I trial of fludarabine and paclitaxel in non-Hodgkin's lymphoma. In: Medical Oncology. 2003 ; Vol. 20, No. 1. pp. 53-58.
@article{92394cf1575f4bea95ef171b5270a226,
title = "Phase I trial of fludarabine and paclitaxel in non-Hodgkin's lymphoma",
abstract = "Fludarabine is an active agent in low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Paclitaxel is also active in patients with refractory lymphoma, and preclinical data suggest an additive effect with fludarabine in vitro. We performed a phase I trial of fludarabine (25 mg/m2 d 1-3) plus a 3-h infusion of paclitaxel (125,150, or 175 mg/m2) on d 3 every 28 d in 13 patients with non-Hodgkin's lymphoma. The paclitaxel dose was escalated in cohorts of 3-4 patients using standard phase I design schema. Dose-limiting toxicity was defined as febrile neutropenia, platelet nadir less than 50,000/μL, or grade 3-4 nonhematologic toxicity. Thirteen patients were accrued to the study, 8 of these 13 patients (62{\%}) had received prior chemotherapy. At the 125-, 150-, and 175-mg/m2 dose levels of paclitaxel, dose-limiting toxicity occurred in 1/4, 0/4, and 0/4 patients, respectively. The single patient with dose-limiting toxicity had febrile neutropenia. Partial response occurred in two of eight patients with low-grade lymphoma and none of five patients with other types of lymphoma. A paclitaxel dose of 175 mg/m2 given as a 3-h infusion on d 3 in conjunction with fludarabine (25 mg/m2 d 1-3 every 4 wk) is a well-tolerated regimen for non-Hodgkin's lymphoma. Further study will be required in order to determine whether the fludarabine-paclitaxel is more active than fludarabine alone in patients with low-grade lymphoma and chronic lymphocytic leukemia.",
keywords = "Fludarabine, Non-Hodgkin's lymphoma, Paclitaxel, Phase I trial",
author = "Abbasi, {Muhammad R.} and Sparano, {Joseph A.} and Catherine Sarta and Wiernik, {Peter H.}",
year = "2003",
doi = "10.1385/MO:20:1:53",
language = "English (US)",
volume = "20",
pages = "53--58",
journal = "Medical Oncology and Tumor Pharmacotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "1",

}

TY - JOUR

T1 - Phase I trial of fludarabine and paclitaxel in non-Hodgkin's lymphoma

AU - Abbasi, Muhammad R.

AU - Sparano, Joseph A.

AU - Sarta, Catherine

AU - Wiernik, Peter H.

PY - 2003

Y1 - 2003

N2 - Fludarabine is an active agent in low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Paclitaxel is also active in patients with refractory lymphoma, and preclinical data suggest an additive effect with fludarabine in vitro. We performed a phase I trial of fludarabine (25 mg/m2 d 1-3) plus a 3-h infusion of paclitaxel (125,150, or 175 mg/m2) on d 3 every 28 d in 13 patients with non-Hodgkin's lymphoma. The paclitaxel dose was escalated in cohorts of 3-4 patients using standard phase I design schema. Dose-limiting toxicity was defined as febrile neutropenia, platelet nadir less than 50,000/μL, or grade 3-4 nonhematologic toxicity. Thirteen patients were accrued to the study, 8 of these 13 patients (62%) had received prior chemotherapy. At the 125-, 150-, and 175-mg/m2 dose levels of paclitaxel, dose-limiting toxicity occurred in 1/4, 0/4, and 0/4 patients, respectively. The single patient with dose-limiting toxicity had febrile neutropenia. Partial response occurred in two of eight patients with low-grade lymphoma and none of five patients with other types of lymphoma. A paclitaxel dose of 175 mg/m2 given as a 3-h infusion on d 3 in conjunction with fludarabine (25 mg/m2 d 1-3 every 4 wk) is a well-tolerated regimen for non-Hodgkin's lymphoma. Further study will be required in order to determine whether the fludarabine-paclitaxel is more active than fludarabine alone in patients with low-grade lymphoma and chronic lymphocytic leukemia.

AB - Fludarabine is an active agent in low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Paclitaxel is also active in patients with refractory lymphoma, and preclinical data suggest an additive effect with fludarabine in vitro. We performed a phase I trial of fludarabine (25 mg/m2 d 1-3) plus a 3-h infusion of paclitaxel (125,150, or 175 mg/m2) on d 3 every 28 d in 13 patients with non-Hodgkin's lymphoma. The paclitaxel dose was escalated in cohorts of 3-4 patients using standard phase I design schema. Dose-limiting toxicity was defined as febrile neutropenia, platelet nadir less than 50,000/μL, or grade 3-4 nonhematologic toxicity. Thirteen patients were accrued to the study, 8 of these 13 patients (62%) had received prior chemotherapy. At the 125-, 150-, and 175-mg/m2 dose levels of paclitaxel, dose-limiting toxicity occurred in 1/4, 0/4, and 0/4 patients, respectively. The single patient with dose-limiting toxicity had febrile neutropenia. Partial response occurred in two of eight patients with low-grade lymphoma and none of five patients with other types of lymphoma. A paclitaxel dose of 175 mg/m2 given as a 3-h infusion on d 3 in conjunction with fludarabine (25 mg/m2 d 1-3 every 4 wk) is a well-tolerated regimen for non-Hodgkin's lymphoma. Further study will be required in order to determine whether the fludarabine-paclitaxel is more active than fludarabine alone in patients with low-grade lymphoma and chronic lymphocytic leukemia.

KW - Fludarabine

KW - Non-Hodgkin's lymphoma

KW - Paclitaxel

KW - Phase I trial

UR - http://www.scopus.com/inward/record.url?scp=0037235771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037235771&partnerID=8YFLogxK

U2 - 10.1385/MO:20:1:53

DO - 10.1385/MO:20:1:53

M3 - Article

C2 - 12665685

AN - SCOPUS:0037235771

VL - 20

SP - 53

EP - 58

JO - Medical Oncology and Tumor Pharmacotherapy

JF - Medical Oncology and Tumor Pharmacotherapy

SN - 0340-7004

IS - 1

ER -